The thrombomodulin/protein C/protein S anticoagulant pathway modulates the thrombogenic properties of the normal resting and stimulated endothelium

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 3, 1997, Pages 520-527

  Cadroy, Y ^a   Diquelou A ^a   Dupouy, D ^a   Bossavy, J P ^a   Sakariassen, K S ^c   Sie P ^b   Boneu, B ^a  

^a CHU PURPAN   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c ALTANA PHARMA AG   (Germany)

Author keywords

endothelium; protein C; protein S; thrombomodulin; thrombosis

Indexed keywords

FIBRIN; IMMUNOGLOBULIN G1; INTERLEUKIN 1; PROTEIN C; PROTEIN S; THROMBOMODULIN;

ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; HUMAN CELL; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; THROMBOGENICITY;

EID: 0030969394     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.3.520     Document Type: Article

References (15)

1. Esmon CT. Thrombomodulin as model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 1995;9:946-955.
2. Seligsohn U, Berger A, Abend M, Rubin L, Attias D, Zivelin A, Rapaport SI. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med. 1984:310:559-562.
3. Koster T, Rosendaal FR, Briët E, van der Meer FJM, Coly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden thrombophilia study). Blood. 1995;85:2756-2761.
4. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Gate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990;323:1512-1518.
5. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as pathogenic factor of venous thromboembolism. Blood. 1995:85:607-614.
6. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994:344:1453-1457.
7. Freyssinet JM, Cazenave JP. Lupus-like anticoagulants, modulation of the protein C pathway and thrombosis. Thromb Haemost. 1987:58:679-681.
8. Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood. 1995:85:330-336.
9. Gomi K, Zushi M, Honda G, Kawahara S, Matsuzaki O, Kanabayashi T, Yamamoto S, Maruyama I, Suzuki K. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood. 1990:75:1396-1399.
10. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987:79:918-925.
11. Gruber A, Griffin JH, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood. 1989;73:639-642.
12. Gruber A, Hanson SR, Kelly AB, Van BS, Bang N, Griffin JH, Harker LA. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation. 1990:82:578-585.
13. Arnljots B, Dahlbäck B. Protein S as an in vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbit. J Clin Invest. 1995:95:1987-1993.
14. Esmon CT. Cell mediated events that control blood coagulation and vascular injury. Anna Rev Cell Biol. 1993;9:1-26.
15. Bevilamia MP, Pober JS, Majeau GR, Fiers W, Contran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1: Proc Natl Acad Sci USA. 1986:83:4533-4537.